evidencegaps
Primary study · included by 1 review

Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.

Bommareddy 2022 · Bommareddy Kanthi, Hamade Hassan, Lopez-Olivo Maria A, et al. · JAMA dermatology · 2022

Included by

Bladder cancer risk factors: a comprehensive umbrella review of meta-analyses.
Non-Cochrane · aetiology · 2026 · cited as Bommareddy 2022 · Table 1 (Included MA); References
Outcome this study informsPooled effectEvidenceCertainty
Risk of bladder cancer
Androgen deprivation therapy vs No androgen suppression therapy
OR 1.00 [0.46, 2.15]4 studies · 242845 participantsVery low
Risk of bladder cancer
With spironolactone vs Without spironolactone
RR 0.89 [0.74, 1.06]3 studies · 254392 participantsVery low

1 including review in total.